

June 28, 2023

Notice regarding Completion of Investment to MED MIRAI, Inc.

Ono Digital health Investment, GK. (a wholly-owned subsidiary of Ono Pharmaceutical Co., Ltd., “ODHI”) today announced that it has completed the investment to MED MIRAI, Inc. (Bunkyo-ku, Tokyo; Representative Director, Tatsuya ONODERA, “MED MIRAI”).

MED MIRAI is a venture company established in May 2021, originating from the University of Tokyo. It provides specific health guidance services utilizing MIRAMED[®], an application developed by the University of Tokyo Center of Innovation -Self Managing Healthy Society- (“the University of Tokyo COI”) *. In addition, MED MIRAI plans to conduct an investigator-initiated trial of MED MIRAI[®], a medical device program targeting metabolic syndrome.

* : The University of Tokyo COI based on its mission of "from hospitalization to outpatient care, from outpatient care to home care, being healthy at home" had been conducting industry-academia collaborative research and development that seamlessly addresses health, pre-disease, and illness, aiming to develop and socially implement diagnostic and therapeutic devices as well as health equipment that can be used safely and simply outside of hospitals. The activities of the University of Tokyo COI has been taken over by the Research Institute for Biomedical Science and Engineering, The University of Tokyo since March 2022.

Metabolic syndrome is a high-risk condition in which visceral fat obesity combined with hypertension, hyperglycemia, and abnormal lipid metabolism increases the risk of heart disease (e.g. myocardial infarction) and cerebrovascular disorders (e.g. cerebral infarction). Prevention and effective treatment options for metabolic syndrome are desired. MED MIRAI has a prevention business using MIRAMED[®] and a treatment support business using MED MIRAI[®], and provides medical care that accompanies individuals in their daily lives.

ODHI was established in March 2022 as a corporate venture capital (CVC) that invests in venture companies in the field of healthcare, other than the ethical pharmaceutical drug-related field. ODHI is committed to extending healthy life expectancy and realizing a sustainable society through the investment in, and collaboration with promising venture companies both in Japan and overseas.

About MED MIRAI, Inc.

Company name: MED MIRAI, Inc.
Address: 7-3-1 Hongo, Bunkyo-ku, Tokyo
Representative Director: Tatsuya ONODERA
Established: May 13, 2021
Business Overview: Provide specific health guidance services and develop medical device programs
URL: <https://www.medmirai.co.jp/>

Ono Digital health Investment, GK.

Company name: Ono Digital health Investment, GK.
Address: 9-11, Nihonbashi-Honcho 4-chome, Chuo-ku, Tokyo
Representative: Masaki ITO, Operating Officer/President
Established: March 8, 2022
Business Overview: Investment in venture companies in the healthcare field, etc.
Capital: 10 million yen
Investment size: 5 billion yen (Including the amount of investment before establishment)
URL: <https://www.onodigitalhealth.com/en>

Contact:

Ono Digital health Investment, GK.
info-onodigi@ono-pharma.com